🇩🇰 Antag Therapeutics announces €80 million Series A financing

— Round led by Versant Ventures with participation from founding investor Novo Holdings and new investors SR One, Dawn Biopharma and Pictet —
— Entering Phase I testing for next-generation weight loss therapy by antagonizing GIPR —

Antag Therapeutics, a next-generation biopharmaceutical company pioneering novel treatments for obesity, today announced the closing of an €80 million Series A financing. The round was led by Versant Ventures, with participation from Novo Holdings, SR One, Dawn Biopharma (a platform controlled by KKR), Pictet, Longview Ventures (an affiliate of Broadview Ventures), and Export and Investment Fund of Denmark (EIFO). The funds will support the clinical development of AT-7687, a novel, once-weekly subcutaneous antagonist of the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR), and also fuel the expansion of Antag’s pipeline of monthly injectable therapies.

GLP-1-based therapies have revolutionized obesity management but can cause tolerability issues, loss of muscle mass, and suboptimal weight loss for some patients. This highlights the need for complementary pharmacological approaches. The genetic basis for antagonizing GIPR is clear. Individuals with naturally occurring genetic GIPR variants that reduce its activity have lower BMI and body fat percentages, resulting in a leaner phenotype compared to those with normal GIPR function.

The development of Antag’s lead molecule is rooted in the groundbreaking identification of an endogenous GIPR antagonist by University of Copenhagen professors Jens Holst, renowned for his discovery of GLP-1, and Mette Rosenkilde. Both co-founded Antag and bring extensive expertise in incretin biology spanning decades. Professor Holst also chairs Antag’s scientific advisory board.

AT-7687 is a peptide designed to be co-administrated with current or future obesity therapies, including GLP-1 medicines, to deliver superior weight loss and metabolic benefits. This flexibility in dosing provides multiple advantages over competing GIPR blockers, such as antibodies directly conjugated to GLP-1. These include the ability to optimally target each for maximal efficacy and tolerability. In addition, AT-7687 can also be used as a single agent in the maintenance setting.

In non-human primate studies, AT-7687 combined with a GLP-1 produced best-in-industry weight loss. Furthermore, AT-7687 improved glycemic control and lipid profiles independent of weight changes. Importantly, these benefits were achieved without gastrointestinal side effects.

The U.S. Food and Drug Administration (FDA) recently accepted Antag’s Investigational New Drug (IND) application for AT-7687, setting the stage for clinical development to begin early next year. The trials will explore the effects of AT-7687 as both a monotherapy and in combination with a GLP-1 receptor agonist in obese patients. Antag’s pipeline also includes combinations beyond GLP-1 receptor agonists and a follow-on molecule that enables monthly administration.

“The backing of such a strong syndicate of global investors is a testament to our pioneering approach to developing novel therapies for patients with obesity,” said Alexander Hovard Sparre-Ulrich, Ph.D., CEO and co-founder of Antag. “Coupled with our recent IND clearance, this investment allows us to accelerate the development of AT-7687 towards important clinical milestones. We believe our first-in-class peptide’s weight loss profile and flexible dosing will be key drivers of differentiation.”

“Antag’s peptides will have important advantages given their ability to be used alone or optimally combined with other incretin-based agents, in both weekly or monthly formats,” said Alex Mayweg, Ph.D., Managing Director at Versant and an Antag board member. “GIP receptor antagonism is just beginning to reveal its incredible potential, both in diabetic and non-diabetic obesity, and we are pleased to be at the forefront of this developing field.”

“Novo Holdings was the first investor in Antag, and we were excited by great science and a world-renowned founder team,” said Jeroen Bakker, Partner, Seed Investments, Novo Holdings. “We are proud to close this Series A round, which brings several blue-chip investors on board. This funding marks a pivotal step in advancing Antag’s pipeline, which we are confident could play a crucial role in further improving the lives of people with obesity.”

About Antag Therapeutics
Antag Therapeutics is a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies for obesity and cardiometabolic diseases through GIP receptor antagonism. As a pioneer in exploring the potential of GIP receptor antagonists, the company is dedicated to advancing science and improving patient outcomes by delivering groundbreaking solutions that address unmet medical needs. For more information, please visit Antag Therapeutics.

About Versant Ventures
Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm emphasizes biotechnology companies that are discovering and developing novel therapeutics. With $5.5 billion under management and offices in the U.S., Canada, and Europe, Versant has built a team with deep investment, operating, and R&D expertise that enables a hands-on approach to company building.

About Novo Holdings A/S
Novo Holdings is a holding and investment company responsible for managing the assets and wealth of the Novo Nordisk Foundation. It invests in life science companies at all stages of development and manages a portfolio of EUR 149 billion as of year-end 2023.

For media inquiries:
Antag Therapeutics
Alexander Sparre-Ulrich, CEO
Email: [email protected]

Originally published on 4 December by Antag Therapeutics.

Announcements are published as a service to readers. The sender is responsible for all content.

Announcements for publication can be submitted to [email protected].